Cancer Control Program, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
J Natl Cancer Inst. 2024 Sep 1;116(9):1450-1458. doi: 10.1093/jnci/djae096.
Anal cancer risk is elevated among people with HIV. Recent anal cancer incidence patterns among people with HIV in the United States and Canada remain unclear. It is unknown how the incidence patterns may evolve.
Using data from the North American AIDS Cohort Collaboration on Research and Design, we investigated absolute anal cancer incidence and incidence trends nationally in the United States and Canada and in different US regions. We further estimated relative risk compared with people without HIV, relative risk among various subgroups, and projected future anal cancer burden among American people with HIV.
Between 2001 and 2016 in the United States, age-standardized anal cancer incidence declined 2.2% per year (95% confidence interval = ‒4.4% to ‒0.1%), particularly in the Western region (‒3.8% per year, 95% confidence interval = ‒6.5% to ‒0.9%). In Canada, incidence remained stable. Considerable geographic variation in risk was observed by US regions (eg, more than 4-fold risk in the Midwest and Southeast compared with the Northeast among men who have sex with men who have HIV). Anal cancer risk increased with a decrease in nadir CD4 cell count and was elevated among those individuals with opportunistic illnesses. Anal cancer burden among American people with HIV is expected to decrease through 2035, but more than 70% of cases will continue to occur in men who have sex with men who have HIV and in people with AIDS.
Geographic variation in anal cancer risk and trends may reflect underlying differences in screening practices and HIV epidemic. Men who have sex with men who have HIV and people with prior AIDS diagnoses will continue to bear the highest anal cancer burden, highlighting the importance of precision prevention.
HIV 感染者的肛门癌风险升高。目前,美国和加拿大 HIV 感染者的肛门癌发病率模式尚不清楚,也不知道这些模式可能会如何演变。
利用北美艾滋病队列协作研究与设计的数据,我们调查了美国和加拿大全国范围内以及不同美国地区的绝对肛门癌发病率和发病率趋势。我们进一步估计了与未感染 HIV 者相比的相对风险、不同亚组之间的相对风险以及美国 HIV 感染者未来的肛门癌负担。
在 2001 年至 2016 年期间,美国的年龄标准化肛门癌发病率每年下降 2.2%(95%置信区间为‒4.4%至‒0.1%),尤其是在西部地区(每年下降 3.8%,95%置信区间为‒6.5%至‒0.9%)。在加拿大,发病率保持稳定。按美国地区划分,风险存在显著的地理差异(例如,在 HIV 感染者中,男男性行为者在中西部和东南部的风险是东北部的 4 倍以上)。肛门癌风险随着最低 CD4 细胞计数的下降而增加,在患有机会性疾病的个体中风险更高。预计到 2035 年,美国 HIV 感染者的肛门癌负担将会减少,但超过 70%的病例仍将发生在 HIV 感染者的男男性行为者和艾滋病患者中。
肛门癌风险和趋势的地理差异可能反映了筛查实践和 HIV 流行的潜在差异。HIV 感染者的男男性行为者和有既往艾滋病诊断的人将继续承受最高的肛门癌负担,突出了精准预防的重要性。